clinical trial · NCT06439602
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302)
GoutArthritis, GoutyHyperuricemiaGout ChronicAR882 50 mgAR882 75 mgPlacebo
brief summary
This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months
started
Jun 26, 2024
primary completion
Nov 1, 2026
completion
Nov 1, 2026
last updated
Apr 15, 2025
official title
A Phase 3 Randomized, Double-blind, Multi-center, Placebo-controlled Study to Evaluate the Efficacy and Safety of AR882 in Participants With Gout
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol